Comparative effectiveness of adipose-derived mesenchymal stromal cells in the management of knee osteoarthritis: A meta-analysis

Table 1 Characteristics of included studies

Sl. No	Ref.	Country	Nature of study	Kellgren Lawrence Grade	Sample size	Treatment/control	Mean age (SD)		Male/female		MSC type	MSC source	Follow-up (mo)
							Treatment group	Control group	Treatment group	Control group
1	Vega et al[23], 2015	Spain	RCT	II, III, IV	30	15/15	56.6 ± 9.24	57.3 ± 9.09	06/09	05/10	BM	Allo	12
2	Vangsness et al[24], 2014	United States	RCT	NR	55	36/19	44.6 ± 9.82	47.8 ± 8	25/11	13/06	BM	Allo	24
3	Garay-Mendoza et al[25], 2018	Mexico	RCT	NR	61	30/31	55.57 ± 12.02	59.32 ± 10.85	07/23	09/22	BM	Auto	6
4	Kuah et al[26], 2018	Australia	RCT	I, II, III	20	16/4	50.8 ± 7.29	55.0 ± 10.42	11/05	01/03	AD	Allo	12
5	Estrada et al[22], 2020	Argentina	RCT	I, II, III	89	60/29	61 ± 12	61 ± 12	NR	NR	BM / AD	Auto	12
6	Freitag et al[27], 2019	Australia	RCT	II, III	30	20/10	54.6 ± 6.3	51.5 ± 6.1	11/09	01/09	AD	Auto	12
7	Ruane et al[41], 2021	United States	RCT	I, II, III	32	17/15	58.06 ± 9.14	58.6 ± 8.05	09/08	10/05	BM	Auto	12
8	Lamo-Espinosa et al[28], 2016	Spain	RCT	II, III, IV	30	20/10	65.9	60.3	12/08	07/03	BM	Auto	12
9	Garza et al[29], 2020	United States	RCT	II, III	39	26/13	60.5 ± 7.9	57.1 ± 9.1	15/11	7/6	AD	Auto	12
10	Wong et al[30], 2013	Singapore	RCT	NR	56	28/28	53	49	15/13	14/14	BM	Auto	24
11	Lu et al[31], 2019	China	RCT	I, II, III	53	27/26	55.03 ± 9.19	59.64 ± 5.97	03/24	03/23	AD	Auto	12
12	Lv et al[42], 2015	Huang	RCT	I, II	80	40/40	55.9 ± 8.1	55.1 ± 6.8	14/26	13/27	BM	Auto	12
13	Emadedin et al[32], 2018	Iran	RCT	II, III, IV	43	19/24	51.7 ± 9.2	54.7 ± 5.3	12/07	15/09	BM	Auto	6
14	Gupta et al[33], 2016	India	RCT	II, III	60	40/20	58.10 ± 8.23	54.90 ± 8.27	12/28	4/16	BM	Allo	12
15	Bastos et al[34], 2020	Brazil	RCT	I, II, III, IV	47	30/17	55.7 ± 7.8	55.9 ± 13.4	15/15	09/08	BM	Auto	12
16	Wakitani et al[35], 2002	Japan		I, II	24	12/12	NR	NR	NR	NR	BM	Auto	16
17	Tran et al[36], 2019	Taiwan	RCT	II, III	33	15/18	58.2 ± 5.70	59.0 ± 6.04	03/12	05/13	AD	Auto	24
18	Lee et al[37], 2019	South Korea	RCT	II, III, IV	24	12/12	62.2 ± 6.5	63.2 ± 4.2	03/09	03/09	AD	Auto	6
19	Koh et al[38], 2012	South Korea	RCT	IV	50	25/25	54.2 ± 9.3	54.4 ± 11.3	08/17	08/17	AD	Auto	16
20	Koh et al[39], 2014	South Korea	RCT	I, II, III	44	23/21	52.3 ± 4.9	54.2 ± 2.9	06/17	05/16	AD	Auto	24
21	Hong et al[40], 2019	China	RCT	II, III	32	16/16	51 ± 5.95	53 ± 10.97	03/13	03/13	AD	Auto	12

AD: Adipose derived; Allo: Allogenic; Auto: Autologous; BM: Bone marrow; MSC: Mesenchymal stem cell; NR: Not reported; RCT: Randomized controlled trial; SD: Standard deviation.